This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
=== End of Empire === By this time, the war was closing in on the embattled Emperor. A Union of Czech Deputies had already sworn an oath to a new Czechoslovak state independent of the Habsburg Empire on 13 April 1918; the prestige of the German Army had taken a severe blow at the Battle of Amiens; and, on 25 September 1918, Zita's brother-in-law King Ferdinand I of Bulgaria broke away from his allies in the Central Powers and sued for peace independently. Zita was with Charles when he received the telegram announcing Bulgaria's collapse. She remembered it "made it even more urgent to start peace talks with the Western Powers while there was still something to talk about." On 16 October, the Emperor issued a "People's Manifesto" proposing the empire be restructured on federal lines with each nationality gaining its own state. Instead, each nation broke away and the empire effectively dissolved. Leaving behind their children at Gödöllő, Charles and Zita travelled to the Schönbrunn Palace. By this time ministers had been appointed by the new state of "German-Austria", and by 11 November, together with the Emperor's spokesmen, they prepared a manifesto for Charles to sign. Zita, at first glance, mistook it for an abdication and made her famous statement:
Global fish production peaked at about 171 million tonnes in 2016, with aquaculture representing 47 percent of the total and 53 percent if non-food uses (including reduction to fishmeal and fish oil) are excluded. With capture fishery production relatively static since the late 1980s, aquaculture has been responsible for the continuing growth in the supply of fish for human consumption. Global aquaculture production (including aquatic plants) in 2016 was 110.2 million tonnes, with the first-sale value estimated at US$244 billion. Three years later, in 2019 the reported output from global aquaculture operations was over 120 million tonnes valued at US$274 billion and by 2022 it had reached 130.9 million tonnes, valued at USD 312.8 billion. For the first time, aquaculture surpassed capture fisheries in aquatic animal production with 94.4 million tonnes, representing 51 percent of the world total and a record 57 percent of the production destined for human consumption. In 2024 aquaculture produced 103 million tonnes of aquatic animals, an all-time record, equivalent to 53% ofglobal aquatic animal output, and over 59% of aquatic animal foods for human consumption. In 2022 most aquaculture workers were in Asia (95%), followed by Africa (3%) and Latin America and the Caribbean (2%). The contribution of aquaculture to the global production of capture fisheries and aquaculture combined has risen continuously, reaching 46.8 percent in 2016, up from 25.7 percent in 2000.
In the next stage of the war, the French drove Russian forces out of Poland and employed many Polish and German soldiers in several sieges in Silesia and Pomerania, with the assistance of Dutch and Italian soldiers in the latter case. Napoleon then turned north to confront the remainder of the Russian army and to try to capture the temporary Prussian capital at Königsberg. A tactical draw at Eylau (7–8 February 1807), followed by capitulation at Danzig (24 May 1807) and the Battle of Heilsberg (10 June 1807), forced the Russians to withdraw further north. Napoleon decisively beat the Russian army at Friedland (14 June 1807), following which Alexander had to make peace with Napoleon at Tilsit (7 July 1807). In Germany and Poland, new Napoleonic client states, such as the Kingdom of Westphalia, Duchy of Warsaw, and Republic of Danzig, were established. By September, Marshal Guillaume Brune completed the occupation of Swedish Pomerania, allowing the Swedish army to withdraw with all its munitions of war.
Sources: en.wikipedia.org
tert-Butyl iodide (systematic name 2-iodo-2-methylpropane) is an organoiodine compound with the formula Me3CI (Me = methyl). The molecule features a tert-butyl group attached to a iodide substituent. This chemical is used as a precursor for the tert-butyl radical in various organic chemical reactions. It can also serve as an electrophile in many types of reactions. Examples include for conversion of amino acids to their tert-butyl esters under mild conditions, Heck reactions and electrophilic aromatic substitutions. In combination with DMSO and an additional oxidizing agent such as iodine, it can convert aryl-methyl groups to the corresponding aryl aldehydes. The reaction is postulated to proceed via generation of an intermediate alkoxysulfonium species.
=== Spinal cord === Neoplastic meningitis (NM) shows diffuse infiltration of tumor cells into the subarachnoid space which may be associated with increased intracranial pressure, signs of meningeal irritation, and damage to the cranial and spinal nerve roots. Pathological feature include:
==== Sharp criteria ==== The Sharp criteria require at least four major criteria, as well as anti-U1-RNP antibody titer of at least 1:4000, or two major criteria from criteria 1, 2, and 3, and two minor criteria, plus anti-U1-RNP antibody titer of at least 1:1000. The Sharp criteria also excludes anyone with a positive anti-Sm antibody. It has a sensitivity of 42% and a specificity of 87.7%. Major criteria:
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.